Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib in Radioiodine-Refractory Differentiated Thyroid Cancer
CTR20160220Phase 2Completed
- Sponsor
- Suzhou Zelgen Biopharmaceuticals
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of donafenib in well-differentiated thyroid cancer (WDTC), sponsored by Suzhou Zelgen Biopharmaceuticals. Started Aug 2016; status: completed.
02
Drugs
donafenib
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on CTR20160220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160220.